Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
Identifieur interne : 001976 ( PubMed/Corpus ); précédent : 001975; suivant : 001977Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
Auteurs : Edward P. Lam ; Cecilia L. Moore ; Eduardo Gotuzzo ; Chidi Nwizu ; Adeeba Kamarulzaman ; Ploenchan Chetchotisakd ; Jean Van Wyk ; Hedy Teppler ; Nagalingeswaran Kumarasamy ; Jean-Michel Molina ; Sean Emery ; David A. Cooper ; Mark A. BoydSource :
- AIDS research and human retroviruses [ 1931-8405 ] ; 2016.
Abstract
We investigate mutations and correlates according to HIV-1 subtype after virological failure (VF) of standard first-line antiretroviral therapy (ART) (non-nucleoside/nucleotide reverse transcriptase inhibitor [NNRTI] +2 nucleoside/nucleotide reverse transcriptase inhibitor [N(t)RTI]). SECOND-LINE study participants were assessed at baseline for HIV-1 subtype, demographics, HIV-1 history, ART exposure, viral load (VL), CD4(+) count, and genotypic ART resistance. We used backward stepwise multivariate regression (MVR) to assess associations between baseline variables and presence of ≥3 N(t)RTI mutations, ≥1 NNRTI mutation, ≥3 thymidine analog-N(t)RTI [ta-N(t)RTI] mutations (TAMs), the K65/K70 mutation, and predicted etravirine (ETV)/rilpivirine (RPV) activity. The inclusion p-value for MVR was p < .2. The exclusion p-value from stepwise elimination was p > .05. Of 541 participants, 491 (91%) had successfully characterized baseline viral isolates. Subtype distribution: B (n = 123, 25%), C (n = 202, 41%), CRF01_AE (n = 109, 22%), G (n = 25, 5%), and CRF02_AG (n = 27, 5%). Baseline CD4(+) 200-394 cells/mm(3) were associated with <3 N(t)RTI mutations (OR = 0.47; 95% CI 0.29-0.77; p = .003), absence of the K65/K70 mutation (OR = 0.43; 95% CI 0.26-0.73; p = .002), and higher ETV sensitivity (OR = 0.52; 95% CI 0.35-0.78; p = .002). Recent tenofovir (TDF) use was associated with K65/K70 mutations (OR = 8.91; 95% CI 5.00-15.85; p < .001). Subtype CRF01_AE was associated with ≥3 N(t)RTI mutations (OR = 2.34; 95% CI 1.31-4.17; p = .004) and higher RPV resistance (OR = 2.13; 95% CI 1.30-3.49; p = .003), and subtype C was associated with <3 TAMs (OR = 0.45; 95% CI 0.21-0.99; p = .015). Subtypes CRF01_AE (OR = 2.46; 95% CI 1.26-4.78; p = .008) and G (OR = 4.77; 95% CI 1.44-15.76; p = .01) were associated with K65/K70 mutations. Higher VL at confirmed first-line VF was associated with ≥3 N(t)RTI mutations (OR = 1.39; 95% CI 1.07-1.78; p = .013) and ≥3 TAMs (OR = 1.62; 95% CI 1.15-2.29; p = .006). The associations of first-line resistance mutations across the HIV-1 subtypes in this study are consistent with knowledge derived from subtype B, with some exceptions. Patterns of resistance after failure of a first-line ta-N(t)RTI regimen support using TDF in N(t)RTI-containing second-line regimens, or using N(t)RTI-sparing regimens.
DOI: 10.1089/AID.2015.0331
PubMed: 27346600
Links to Exploration step
pubmed:27346600Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.</title><author><name sortKey="Lam, Edward P" sort="Lam, Edward P" uniqKey="Lam E" first="Edward P" last="Lam">Edward P. Lam</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author><author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author><author><name sortKey="Gotuzzo, Eduardo" sort="Gotuzzo, Eduardo" uniqKey="Gotuzzo E" first="Eduardo" last="Gotuzzo">Eduardo Gotuzzo</name><affiliation><nlm:affiliation>2 Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano , Heredia, Lima, Peru .</nlm:affiliation></affiliation></author><author><name sortKey="Nwizu, Chidi" sort="Nwizu, Chidi" uniqKey="Nwizu C" first="Chidi" last="Nwizu">Chidi Nwizu</name><affiliation><nlm:affiliation>3 Center for Clinical Care and Clinical Research in Nigeria , Abuja, Nigeria .</nlm:affiliation></affiliation></author><author><name sortKey="Kamarulzaman, Adeeba" sort="Kamarulzaman, Adeeba" uniqKey="Kamarulzaman A" first="Adeeba" last="Kamarulzaman">Adeeba Kamarulzaman</name><affiliation><nlm:affiliation>4 Clinical Investigations Centre, University of Malaya , Kuala Lumpur, Malaysia .</nlm:affiliation></affiliation></author><author><name sortKey="Chetchotisakd, Ploenchan" sort="Chetchotisakd, Ploenchan" uniqKey="Chetchotisakd P" first="Ploenchan" last="Chetchotisakd">Ploenchan Chetchotisakd</name><affiliation><nlm:affiliation>5 Infectious Diseases Unit, Srinagarind Hospital, Khon Kaen University , Thailand .</nlm:affiliation></affiliation></author><author><name sortKey="Van Wyk, Jean" sort="Van Wyk, Jean" uniqKey="Van Wyk J" first="Jean" last="Van Wyk">Jean Van Wyk</name><affiliation><nlm:affiliation>6 AbbVie, North Chicago, Illinois.</nlm:affiliation></affiliation></author><author><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name><affiliation><nlm:affiliation>7 Merck & Co., Inc. , Kenilworth, New Jersey.</nlm:affiliation></affiliation></author><author><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name><affiliation><nlm:affiliation>8 YRG Care, Chennai, India .</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation><nlm:affiliation>9 Department of Clinical Infectious Diseases, Hôpital Saint-Louis , Paris, France .</nlm:affiliation></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27346600</idno><idno type="pmid">27346600</idno><idno type="doi">10.1089/AID.2015.0331</idno><idno type="wicri:Area/PubMed/Corpus">001976</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001976</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.</title><author><name sortKey="Lam, Edward P" sort="Lam, Edward P" uniqKey="Lam E" first="Edward P" last="Lam">Edward P. Lam</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author><author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author><author><name sortKey="Gotuzzo, Eduardo" sort="Gotuzzo, Eduardo" uniqKey="Gotuzzo E" first="Eduardo" last="Gotuzzo">Eduardo Gotuzzo</name><affiliation><nlm:affiliation>2 Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano , Heredia, Lima, Peru .</nlm:affiliation></affiliation></author><author><name sortKey="Nwizu, Chidi" sort="Nwizu, Chidi" uniqKey="Nwizu C" first="Chidi" last="Nwizu">Chidi Nwizu</name><affiliation><nlm:affiliation>3 Center for Clinical Care and Clinical Research in Nigeria , Abuja, Nigeria .</nlm:affiliation></affiliation></author><author><name sortKey="Kamarulzaman, Adeeba" sort="Kamarulzaman, Adeeba" uniqKey="Kamarulzaman A" first="Adeeba" last="Kamarulzaman">Adeeba Kamarulzaman</name><affiliation><nlm:affiliation>4 Clinical Investigations Centre, University of Malaya , Kuala Lumpur, Malaysia .</nlm:affiliation></affiliation></author><author><name sortKey="Chetchotisakd, Ploenchan" sort="Chetchotisakd, Ploenchan" uniqKey="Chetchotisakd P" first="Ploenchan" last="Chetchotisakd">Ploenchan Chetchotisakd</name><affiliation><nlm:affiliation>5 Infectious Diseases Unit, Srinagarind Hospital, Khon Kaen University , Thailand .</nlm:affiliation></affiliation></author><author><name sortKey="Van Wyk, Jean" sort="Van Wyk, Jean" uniqKey="Van Wyk J" first="Jean" last="Van Wyk">Jean Van Wyk</name><affiliation><nlm:affiliation>6 AbbVie, North Chicago, Illinois.</nlm:affiliation></affiliation></author><author><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name><affiliation><nlm:affiliation>7 Merck & Co., Inc. , Kenilworth, New Jersey.</nlm:affiliation></affiliation></author><author><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name><affiliation><nlm:affiliation>8 YRG Care, Chennai, India .</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation><nlm:affiliation>9 Department of Clinical Infectious Diseases, Hôpital Saint-Louis , Paris, France .</nlm:affiliation></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><affiliation><nlm:affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</nlm:affiliation></affiliation></author></analytic><series><title level="j">AIDS research and human retroviruses</title><idno type="eISSN">1931-8405</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigate mutations and correlates according to HIV-1 subtype after virological failure (VF) of standard first-line antiretroviral therapy (ART) (non-nucleoside/nucleotide reverse transcriptase inhibitor [NNRTI] +2 nucleoside/nucleotide reverse transcriptase inhibitor [N(t)RTI]). SECOND-LINE study participants were assessed at baseline for HIV-1 subtype, demographics, HIV-1 history, ART exposure, viral load (VL), CD4(+) count, and genotypic ART resistance. We used backward stepwise multivariate regression (MVR) to assess associations between baseline variables and presence of ≥3 N(t)RTI mutations, ≥1 NNRTI mutation, ≥3 thymidine analog-N(t)RTI [ta-N(t)RTI] mutations (TAMs), the K65/K70 mutation, and predicted etravirine (ETV)/rilpivirine (RPV) activity. The inclusion p-value for MVR was p < .2. The exclusion p-value from stepwise elimination was p > .05. Of 541 participants, 491 (91%) had successfully characterized baseline viral isolates. Subtype distribution: B (n = 123, 25%), C (n = 202, 41%), CRF01_AE (n = 109, 22%), G (n = 25, 5%), and CRF02_AG (n = 27, 5%). Baseline CD4(+) 200-394 cells/mm(3) were associated with <3 N(t)RTI mutations (OR = 0.47; 95% CI 0.29-0.77; p = .003), absence of the K65/K70 mutation (OR = 0.43; 95% CI 0.26-0.73; p = .002), and higher ETV sensitivity (OR = 0.52; 95% CI 0.35-0.78; p = .002). Recent tenofovir (TDF) use was associated with K65/K70 mutations (OR = 8.91; 95% CI 5.00-15.85; p < .001). Subtype CRF01_AE was associated with ≥3 N(t)RTI mutations (OR = 2.34; 95% CI 1.31-4.17; p = .004) and higher RPV resistance (OR = 2.13; 95% CI 1.30-3.49; p = .003), and subtype C was associated with <3 TAMs (OR = 0.45; 95% CI 0.21-0.99; p = .015). Subtypes CRF01_AE (OR = 2.46; 95% CI 1.26-4.78; p = .008) and G (OR = 4.77; 95% CI 1.44-15.76; p = .01) were associated with K65/K70 mutations. Higher VL at confirmed first-line VF was associated with ≥3 N(t)RTI mutations (OR = 1.39; 95% CI 1.07-1.78; p = .013) and ≥3 TAMs (OR = 1.62; 95% CI 1.15-2.29; p = .006). The associations of first-line resistance mutations across the HIV-1 subtypes in this study are consistent with knowledge derived from subtype B, with some exceptions. Patterns of resistance after failure of a first-line ta-N(t)RTI regimen support using TDF in N(t)RTI-containing second-line regimens, or using N(t)RTI-sparing regimens.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27346600</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>02</Day></DateCreated><DateRevised><Year>2016</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1931-8405</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>AIDS research and human retroviruses</Title><ISOAbbreviation>AIDS Res. Hum. Retroviruses</ISOAbbreviation></Journal><ArticleTitle>Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.</ArticleTitle><Pagination><MedlinePgn>841-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/AID.2015.0331</ELocationID><Abstract><AbstractText>We investigate mutations and correlates according to HIV-1 subtype after virological failure (VF) of standard first-line antiretroviral therapy (ART) (non-nucleoside/nucleotide reverse transcriptase inhibitor [NNRTI] +2 nucleoside/nucleotide reverse transcriptase inhibitor [N(t)RTI]). SECOND-LINE study participants were assessed at baseline for HIV-1 subtype, demographics, HIV-1 history, ART exposure, viral load (VL), CD4(+) count, and genotypic ART resistance. We used backward stepwise multivariate regression (MVR) to assess associations between baseline variables and presence of ≥3 N(t)RTI mutations, ≥1 NNRTI mutation, ≥3 thymidine analog-N(t)RTI [ta-N(t)RTI] mutations (TAMs), the K65/K70 mutation, and predicted etravirine (ETV)/rilpivirine (RPV) activity. The inclusion p-value for MVR was p < .2. The exclusion p-value from stepwise elimination was p > .05. Of 541 participants, 491 (91%) had successfully characterized baseline viral isolates. Subtype distribution: B (n = 123, 25%), C (n = 202, 41%), CRF01_AE (n = 109, 22%), G (n = 25, 5%), and CRF02_AG (n = 27, 5%). Baseline CD4(+) 200-394 cells/mm(3) were associated with <3 N(t)RTI mutations (OR = 0.47; 95% CI 0.29-0.77; p = .003), absence of the K65/K70 mutation (OR = 0.43; 95% CI 0.26-0.73; p = .002), and higher ETV sensitivity (OR = 0.52; 95% CI 0.35-0.78; p = .002). Recent tenofovir (TDF) use was associated with K65/K70 mutations (OR = 8.91; 95% CI 5.00-15.85; p < .001). Subtype CRF01_AE was associated with ≥3 N(t)RTI mutations (OR = 2.34; 95% CI 1.31-4.17; p = .004) and higher RPV resistance (OR = 2.13; 95% CI 1.30-3.49; p = .003), and subtype C was associated with <3 TAMs (OR = 0.45; 95% CI 0.21-0.99; p = .015). Subtypes CRF01_AE (OR = 2.46; 95% CI 1.26-4.78; p = .008) and G (OR = 4.77; 95% CI 1.44-15.76; p = .01) were associated with K65/K70 mutations. Higher VL at confirmed first-line VF was associated with ≥3 N(t)RTI mutations (OR = 1.39; 95% CI 1.07-1.78; p = .013) and ≥3 TAMs (OR = 1.62; 95% CI 1.15-2.29; p = .006). The associations of first-line resistance mutations across the HIV-1 subtypes in this study are consistent with knowledge derived from subtype B, with some exceptions. Patterns of resistance after failure of a first-line ta-N(t)RTI regimen support using TDF in N(t)RTI-containing second-line regimens, or using N(t)RTI-sparing regimens.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Edward P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Cecilia L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotuzzo</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>2 Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano , Heredia, Lima, Peru .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nwizu</LastName><ForeName>Chidi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>3 Center for Clinical Care and Clinical Research in Nigeria , Abuja, Nigeria .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamarulzaman</LastName><ForeName>Adeeba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>4 Clinical Investigations Centre, University of Malaya , Kuala Lumpur, Malaysia .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chetchotisakd</LastName><ForeName>Ploenchan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>5 Infectious Diseases Unit, Srinagarind Hospital, Khon Kaen University , Thailand .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wyk</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>6 AbbVie, North Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teppler</LastName><ForeName>Hedy</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>7 Merck & Co., Inc. , Kenilworth, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumarasamy</LastName><ForeName>Nagalingeswaran</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>8 YRG Care, Chennai, India .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>9 Department of Clinical Infectious Diseases, Hôpital Saint-Louis , Paris, France .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emery</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>1 The Kirby Institute UNSW Australia , Sydney, Australia .</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10 University of Adelaide , Lyell McEwin Hospital, Adelaide, South Australia, Australia .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AIDS Res Hum Retroviruses</MedlineTA><NlmUniqueID>8709376</NlmUniqueID><ISSNLinking>0889-2229</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27346600</ArticleId><ArticleId IdType="doi">10.1089/AID.2015.0331</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001976 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001976 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27346600
|texte= Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27346600" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |